Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), remains the leading cause of mortality from a single infectious agent. Each year around 9 million individuals newly develop active TB disease, and over 2 billion individuals are latently infected with M.tb worldwide, thus being at risk of developing TB reactivation disease later in life. The underlying mechanisms and pathways of protection against TB in humans, as well as the dynamics of the host response to M.tb infection, are incompletely understood. We carried out whole-genome expression profiling on a cohort of TB patients longitudinally sampled along 3 time-points: during active infection, during treatment, and after completion of curative treatment. We identified molecular signatures involving the upregulation of type-1 interferon (α/β) mediated signaling and chronic inflammation during active TB disease in an Indonesian population, in line with results from two recent studies in ethnically and epidemiologically different populations in Europe and South Africa. Expression profiles were captured in neutrophil-depleted blood samples, indicating a major contribution of lymphocytes and myeloid cells. Expression of type-1 interferon (α/β) genes mediated was also upregulated in the lungs of M.tb infected mice and in infected human macrophages. In patients, the regulated gene expression-signature normalized during treatment, including the type-1 interferon mediated signaling and a concurrent opposite regulation of interferon-gamma. Further analysis revealed IL15RA, UBE2L6 and GBP4 as molecules involved in the type-I interferon response in all three experimental models. Our data is highly suggestive that the innate immune type-I interferon signaling cascade could be used as a quantitative tool for monitoring active TB disease, and provide evidence that components of the patient’s blood gene expression signature bear similarities to the pulmonary and macrophage response to mycobacterial infection.
References
[1]
Raviglione MC (2003) The TB epidemic from 1992 to 2002. Tuberculosis 83: 4–14.
[2]
Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, et al. (2009) Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection. PLoS ONE 4: e5590.
[3]
Ottenhoff TH, Kaufmann SH (2012) Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 8: e1002607.
[4]
Ottenhoff TH, Ellner JJ, Kaufmann SH (2012) Ten challenges for TB biomarkers. Tuberculosis (Edinb ) 92 Suppl 1S17–S20.
[5]
van de Vosse E, van Dissel JT, Ottenhoff TH (2009) Genetic deficiencies of innate immune signaling in human infectious disease. Lancet Infect Dis 9: 688–698.
[6]
de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, et al. (1998) Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280: 1435–1438.
[7]
Levin M, Newport M (2000) Inherited predisposition to mycobacterial infection: historical considerations. Microbes Infect 2: 1549–1552.
[8]
Ottenhoff THM (2012) New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 2012 (9 July Epub ahead of print).
[9]
Mistry R, Cliff JM, Clayton CL, Beyers N, Mohamed YS, et al. (2007) Gene-Expression Patterns in Whole Blood Identify Subjects at Risk for Recurrent Tuberculosis. J Infect Dis 195: 357–365.
[10]
Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, et al. (2007) Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 85: 613–621.
[11]
Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, et al. (2011) Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun 13: 71–82.
[12]
Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, et al. (2011) Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 12: 15–22.
[13]
Maertzdorf J, Ota M, Repsilber D, Mollenkopf HJ, Weiner J, et al. (2011) Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS ONE 6: e26938.
[14]
Lesho E, Forestiero FJ, Hirata MH, Hirata RD, Cecon L, et al. (2011) Transcriptional responses of host peripheral blood cells to tuberculosis infection. Tuberculosis (Edinb ) 91: 390–399.
[15]
Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, et al. (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973–977.
[16]
Maertzdorf J, Weiner J, Mollenkopf HJ, TBornotTB Network, Bauer T, et al. (2012) Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 109: 7853–7858.
[17]
Abebe M, Doherty TM, Wassie L, Aseffa A, Bobosha K, et al. (2010) Expression of apoptosis-related genes in an Ethiopian cohort study correlates with tuberculosis clinical status. Eur J Immunol 40: 291–301.
[18]
Schafer G, Guler R, Murray G, Brombacher F, Brown GD (2009) The Role of Scavenger Receptor B1 in Infection with Mycobacterium tuberculosis in a Murine Model. PLoS ONE 4: e8448.
[19]
Dharmadhikari AS, Nardell EA (2008) What Animal Models Teach Humans about Tuberculosis. Am J Respir Cell Mol Biol 39: 503–508.
[20]
Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, et al. (2002) Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 32: 97–105.
[21]
Korbel DS, Schneider BE, Schaible UE (2008) Innate immunity in tuberculosis: myths and truth. Microbes Infect 10: 995–1004.
[22]
van de Wetering D, van Wengen A, Savage ND, van de Vosse E, van Dissel JT (2011) IFN-α cannot substitute lack of IFN-γ responsiveness in cells of an IFN-γR1 deficient patient. Clin Immunol 138: 282–290.
[23]
Kuchtey J, Fulton SA, Reba SM, Harding CV, Boom WH (2006) Interferon-αβ mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guérin infection. Immunology 118: 39–49.
[24]
Desvignes L, Wolf AJ, Ernst JD (2012) Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J Immunol 188: 6205–6215.
[25]
de Paus RA, van Wengen A, Schmidt I, Visser M, Verdegaal EME, et al.. (2012) Inhibition of the type I immune responses of human monocytes by IFN-α and IFN-β. submitted.
[26]
Sinai AP, Joiner KA (1997) Safe Haven: The Cell Biology of Nonfusogenic Pathogen Vacuoles. Annu Rev Microbiol 51: 415–462.
[27]
Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, et al. (2004) Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119: 753–766.
[28]
Petruccioli E, Romagnoli A, Corazzari M, Coccia EM, Butera O, et al. (2012) Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages. J Infect Dis 205: 1425–1435.
[29]
Davila S, Hibberd ML, Hari Dass R, Wong HE, Sahiratmadja E, et al. (2008) Genetic association and expression studies indicate a role of Toll-Like Receptor 8 in pulmonary tuberculosis. PLoS Genet 4: e1000218.
[30]
Wong RL, Liu B, Zhu X, You L, Kong L, et al. (2011) Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules. Protein Eng Des Sel 24: 373–383.
[31]
Mortier E, Advincula R, Kim L, Chmura S, Barrera J, et al. (2009) Macrophage- and Dendritic-Cell-Derived Interleukin-15 Receptor Alpha Supports Homeostasis of Distinct CD8+ T Cell Subsets. Immunity 31: 811–822.
[32]
Oshiumi H, Miyashita M, Inoue N, Okabe M, Matsumoto M, et al. (2010) The Ubiquitin Ligase Riplet Is Essential for RIG-I-Dependent Innate Immune Responses to RNA Virus Infection. Cell Host Microbe 8: 496–509.
[33]
Arimoto Ki, Takahashi H, Hishiki T, Konishi H, Fujita T, et al. (2007) Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc Natl Acad Sci USA 104: 7500–7505.
[34]
Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, et al. (2004) The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN- α/β-induced ubiquitin-like protein. Proc Natl Acad Sci USA 101: 7578–7582.
[35]
Jeon YJ, Choi JS, Lee JY, Yu KR, Kim SM, et al. (2009) ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. EMBO Rep 10: 374–380.
[36]
Decker T, Lew DJ, Darnell JE (1991) Two distinct alpha-interferon-dependent signal transduction pathways may contribute to activation of transcription of the guanylate-binding protein gene. Mol Cell Biol 11: 5147–5153.
[37]
Sahiratmadja E, Alisjahbana B, de Boer T, Adnan I, Maya A, et al. (2007) Dynamic changes in pro- and anti-inflammatory cytokine profiles (IFN-γ, TNF-α, IL-12/23, and IL-10) and IFN-γ receptor signalling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun 75: 820–829.
[38]
WHO (2012) Global Health Observatory Data Repository. Available at: http://apps.who.int/ghodata/(last accessed August 2012).
[39]
Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, et al. (2006) Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 8: 2052–2060.
